Klin Farmakol Farm. 2023;37(4):160-164 | DOI: 10.36290/far.2023.028

Surgical treatment of bicalutamide-induced gynecomastia, an overview of selected drugs causing unwanted effects of gynecomastia

Júlia Bartková1, 2, 3, Dominika Miklišová3, Miroslava Verbat3, Ema Šutaková4, Alžběta Novotná3, Zuzana Jelinková2, Bretislav Lipový
1 Klinika popáleninové medicíny, 3. lekárska fakulta, Univerzita Karlova, Praha, Česká republika; Fakultná nemocnica Královské Vinohrady, Praha, Česká republika
2 Klinika popálenin a plastické chirurgie Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice Brno
3 Lekárska fakulta Masarykovej univerzity Brno, Česká republika
4 I. lekárska fakulta – Univerzita Karlova Praha, Česká republika
5 II. lekárska fakulta Univerzita Karlova Praha, Česká republika

Gynecomastia, the enlargement of male breast tissue, is usually caused by hormonal imbalances between estrogen and testosterone levels. However, it can also be caused by a multitude of factors, such as tumors, obesity, hypogonadism, androgen insensitivity syndrome, thyrotoxicosis, or the use of numerous medications. As an example, we present a patient with gynecomastia which developed after a long-term treatment with bicalutamide for prostate cancer. Due to this adverse effect of his medication, our patient experienced significant anxiety and discomfort in his daily life. Therefore, a bilateral mastectomy in combination with liposuction was chosen for his treatment. Since drug-induced gynecomastia contributes to almost a quarter of all gynecomastia cases, we provide an overview of various other medications responsible for this condition.

Keywords: gynecomastia, bicalutamide, prostate cancer, side effects.

Accepted: December 13, 2023; Published: December 20, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartková J, Miklišová D, Verbat M, Šutaková E, Novotná A, Jelinková Z, Lipový B. Surgical treatment of bicalutamide-induced gynecomastia, an overview of selected drugs causing unwanted effects of gynecomastia. Klin Farmakol Farm. 2023;37(4):160-164. doi: 10.36290/far.2023.028.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Niewoehner CB, Nuttal FQ. Gynecomastia in a hospitalized male population. The American journal of medicine. 1984;77(4):633-638. Available from: https://doi.org/10.1016/0002-9343(84)90353-x. Go to original source... Go to PubMed...
    2. Nuttall FQ. Gynecomastia as a physical finding in normal men. The Journal of clinical endocrinology and metabolism. 1979;48(2):338-340. Available from: https://doi.org/10.1210/jcem-48-2-338. Go to original source... Go to PubMed...
    3. Ordaz DL, Thompson JK. Gynecomastia and psychological functioning: A review of the literature. Body Image. 2015;15:141-148. Available from: https://doi.org/10.1016/j.bodyim.2015.08.004. Go to original source... Go to PubMed...
    4. Miklisova D, Verbat M, Sutakova E, et al. Surgical treatment of Bicalutamide-induced gynecomastia. In: PlastSurgeon.com [on-line]. 2023 May [cited 2023 August 06]. Available from: https://plastsurgeon.com/case-competition-overview/case-competition-2023/case-17-surgical-excision-of-bicalutamide-induced-gynecomastia/.
    5. Fagerlund A, Cormio L, Palangi L, et al. Gynecomastia in Patients with Prostate Cancer: A Systematic Review. PloS one. 2015;10(8):e0136094. Available from: https://doi.org/10.1371/journal.pone.0136094. Go to original source... Go to PubMed...
    6. Di Lorenzo G, Autorino R. Bicalutamide-Induced Gynaecomastia: Do We Have the Answer? European Urology. 2007;52(1):5-8. Available from: https://doi.org/10.1016/j.eururo.2007.01.063. Go to original source... Go to PubMed...
    7. Ritter JM, Robinson E, Fullerton J, et al. Rang & Dale's Pharmacology (9th ed.) [on-line]. Elsevier - OHCE; 2018. Available from: https://bookshelf.health.elsevier.com/books/9780702074455.
    8. Souhrn údajů O přípravku Bicaluplex - Sukl.cz. Státní ústav pro kontrolu léčiv. (n.d.-a). [on-line]. Available from: https://prehledy.sukl.cz/prehledy/v1/dokumenty/16464.
    9. Haynes BA, Mookadam F. Male gynecomastia. Mayo Clinic proceedings. 2009;84(8):672. Available from: https://doi.org/10.1016/S0025-6196(11)60515-6. Go to original source...
    10. Jeunemaitre X, Kreft-Jais C, Chatellier G, et al. Long-term experience of spironolactone in essential hypertension. Kidney Int Suppl. 1988;26:S14-S17. Available from: https://pubmed.ncbi.nlm.nih.gov/3199684/.
    11. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29(1):64-73. doi:10.1592/phco.29.1.64. Go to original source... Go to PubMed...
    12. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050-1057. doi:10.4065/80.8.1050. Go to original source... Go to PubMed...
    13. Mendhekar DN, Andrade CR. Unilateral gynecomastia induced by risperidone in a geriatric male patient. Indian J Med Sci. 2005;59(8):361-362. Go to original source...
    14. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-2314. doi:10.2165/00003495-200464200-00003. Go to original source... Go to PubMed...
    15. Mabini R, Wergowske G, Baker FM. Galactorrhea and gynecomastia in a hypothyroid male being treated with risperidone. Psychiatr Serv Wash DC. 2000;51(8):983-985. doi:10.1176/appi.ps.51.8.983. Go to original source... Go to PubMed...
    16. Benazzi F. Gynecomastia with risperidone-fluoxetine combination. Pharmacopsychiatry. 1999;32(1):41. doi:10.1055/ s-2007-979187. Go to original source... Go to PubMed...
    17. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19(1):57-61. doi:10.1097/00004714-199902000-00011. Go to original source... Go to PubMed...
    18. Shahi MK, Kar SK. Asymmetric, Tender Gynecomastia Induced by Olanzapine in a Young Male. Indian J Psychol Med. 2017;39(2):215-216. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385759/. Go to original source... Go to PubMed...
    19. Aiman U, Haseeen MA, Rahman SZ. Gynecomastia: An ADR due to drug interaction. Indian journal of pharmacology. 2009;41(6):286-287. Available from: https://doi.org/10.4103/0253-7613.59929. Go to original source... Go to PubMed...
    20. He B, Carleton B, Etminan M. Risk of Gynecomastia with Users of Proton Pump Inhibitors. Pharmacotherapy. 2019;39(5):614-618. Available from: https://doi.org/10.1002/phar.2245. Go to original source... Go to PubMed...
    21. Bowman JD, Kim H, Bustamante JJ. Drug-induced gynecomastia. Pharmacotherapy. 2012;32(12):1123-1140. doi:10.1002/phar.1138. Go to original source... Go to PubMed...
    22. Wilt TJ, Macdonald R, Hagerty K, et al. 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int. 2010;106(10):1444-1451. doi:10.1111/j.1464-410X.2010.09714.x. Go to original source... Go to PubMed...
    23. DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother. 1981;19(6): 1073-1074. doi:10.1128/AAC.19.6.1073. Go to original source... Go to PubMed...
    24. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050-1057. doi:10.4065/80.8.1050. Go to original source... Go to PubMed...
    25. Klein JJ, Segal RL, Warner RRP. Galactorrhea Due to Imipramine. Available from: http://dx.doi.org/10.1056/NEJM196409032711008. doi:10.1056/NEJM196409032711008. Go to original source...
    26. Anand VS. Clomipramine-induced galactorrhoea and amenorrhoea. Br J Psychiatry J Ment Sci. 1985;147:87-88. doi:10.1192/bjp.147.1.87. Go to original source... Go to PubMed...
    27. Arroyo H. Gynecomastia induced by a monoamine oxidase inhibitor. Presse Med. 1966;74(34):1764.
    28. Bronzo MR, Stahl SM. Galactorrhea induced by sertraline. Am J Psychiatry. 1993;150(8):1269-1270. doi:10.1176/ajp. 150.8.1269a. Go to original source... Go to PubMed...
    29. Hall MJ. Breast tenderness and enlargement induced by sertraline. Am J Psychiatry. 1994;151(9):1395-1396. doi:10.1176/ajp.151.9.1395b. Go to original source... Go to PubMed...
    30. Karakurt F, Kargili A, Uz B, et al. Venlafaxine-induced gynecomastia in a young patient: a case report. Clin Neuropharmacol. 2009;32(1):51-52. doi:10.1097/WNF.0B013E3181679126. Go to original source... Go to PubMed...
    31. Weydt P, Schönfeldt-Lecuona CJ, Gahr M, et al. Hypogonadism and gynecomastia with duloxetine. Pharmacopsychiatry. 2011;44(2):77. doi:10.1055/s-0031-1271684. Go to original source... Go to PubMed...
    32. Damsa C, Bumb A, Bianchi-Demicheli F, et al. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry. 2004;65(8):1064-1068. doi:10.4088/jcp.v65n0806. Go to original source... Go to PubMed...
    33. Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. Eur J Clin Pharmacol. 2015;71(5):569-578. doi:10.1007/s00228-015-1835-x. Go to original source... Go to PubMed...
    34. European database of suspected adverse drug reaction reports [on-line]. Available from: http://www.adrreports.eu/en/search_subst.html#. [cited 2023 October 15].
    35. Swerdloff RS. MACP Gynecomastia: Etiology, Diagnosis, and Treatment [on-line]. Endotext; 2023. Available from: .https://www.ncbi.nlm.nih.gov/books/NBK279105/#:~:text=There%20are%203%20classes%20of,such%20as%20letrozole%20and%20anastrozole.
    36. Mett TR, Pfeiler PP. Surgical treatment of gynaecomastia: a standard of care in plastic surgery. European Journal of Plastic Surgery. 2020;43:389-398. Available from: https://link.springer.com/article/10.1007/s00238-019-01617-8#ref-CR1. Go to original source...
    37. More Men Undergo Plastic Surgery as the Daddy-Do-Over Trend Rises in Popularity. American Society of Plastic Surgeons, 2018 National Clearinghouse of Plastic Surgery Available from: https://www.plasticsurgery.org/news/press-releases/more-men-undergo-plastic-surgery-as-the-daddy-do-over-trend-rises-in-popularity.
    38. He W, Wei W. A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastia. BMC Endocrine Disorders. 2023;Article number: 62. Available from: https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-023-01310-9#:~:text=In%20one%20cohort%20study%2C%20TAM,than%2012%20months%20%5B12%5D.
    39. Fricke A, Lehner GM, Stark GB, et al. Long-Term Follow-up of Recurrence and Patient Satisfaction After Surgical Treatment of Gynecomastia. Aesthetic plastic surgery. 2017;41(3):491-498. Available from: https://doi.org/10.1007/s00266-017-0827-x). Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.